Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.59    -0.31 (-10.69%)
Bid:
2.60
Ask:
2.91
Spread: 0.31 (11.923%)
Market Cap: £4.73m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Litigation Update

17 May 2022 07:02

RNS Number : 7448L
Nanoco Group PLC
17 May 2022
 

FOR IMMEDIATE RELEASE 17 May 2022

Nanoco Group PLC

("Nanoco, the "Group", or the "Company")

 

Litigation Update - PTAB uphold all 47 Nanoco patent claims

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from its technology platform, announces a significant update to its litigation against Samsung for the willful infringement of the Group's IP.

 

The US Patent Trial and Appeal Board ('PTAB') has ruled in favour of Nanoco in respect of all 47 claims in the five patents that were subject to inter partes review (IPRs) in the case.

 

As previously announced, Samsung had applied to the PTAB requesting the institution of IPRs of each of the five patents in the case. An IPR is a standard part of IP litigation and examines the validity of the patents themselves. It often runs in parallel with the judicial process. In May 2021, PTAB announced its decision to institute IPRs over the five patents.

 

The Board and its advisers are reviewing the detailed ruling by the PTAB with respect to all of the claims and patents. While Samsung can be expected to appeal the final PTAB decisions, the Company believes it is likely that the stay on the court process will now be lifted at the hearing scheduled for 2 June 2022 in the Eastern District of Texas. If the stay is lifted, pre-trial motions will then be considered by the judge and the Company expects a revised trial date to be scheduled for the fourth quarter of calendar year 2022.

 

Brian Tenner, Chief Executive Officer of Nanoco Group plc, said:

"The strength of Nanoco's case has been amply demonstrated by the PTAB finding in favour of every single one of the 47 claims under the five patents. The question of the validity of our intellectual property has now been very clearly resolved in favour of Nanoco.

 

"As a result, the trial can now focus on the issue of Samsung's alleged wilful infringement and the appropriate level of damages.

 

"Nanoco has overcome the first of two major hurdles in the litigation, the validity of our IP. As a result, our confidence in this case has increased further. While there is still much to be done, successfully overcoming this hurdle allows a straight run in to a trial later in 2022. A favourable trial outcome should then deliver a substantial inflection point for Nanoco's prospects and shareholder value."

 

- Ends -

 

For further information, please contact:

Nanoco Group PLC:

Brian Tenner, CEO +44 (0) 161 603 7900

Liam Gray, CFO & Company Secretary +44 (0) 161 603 7900

 

Peel Hunt:

Edward Knight +44 (0) 20 7418 8900

James Smith

 

MHP Communications: +44 (0) 203 128 8990

Reg Hoare

Pete Lambie

Charlie Protheroe

nanoco@mhpc.com 

 

The person responsible for arranging for the release of this announcement on behalf of Nanoco is Liam Gray, Company Secretary.

MAR

This Announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 which is part of UK law by virtue of the European Union (withdrawal) Act 2018. Upon the publication of this announcement via a Regulatory Information Service, this inside information will be considered to be in the public domain.

FORWARD LOOKING STATEMENTS

This announcement (including information incorporated by reference in this announcement) and other information published by Nanoco may contain statements about Nanoco that are or may be deemed to be forward looking statements. Such statements are prospective in nature. All statements other than historical statements of facts may be forward looking statements. Without limitation, statements containing the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects" or "considers" or other similar words may be forward looking statements.

Forward looking statements inherently contain risks and uncertainties as they relate to events or circumstances in the future. Important factors such as business or economic cycles, the terms and conditions of Nanoco's financing arrangements, tax rates, or increased competition may cause Nanoco's actual financial results, performance or achievements to differ materially from any forward looking statements. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward looking statements, which speak only as of the date hereof. Nanoco disclaims any obligation to update any forward looking or other statements contained herein, except as required by applicable law.

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots and other nano-materials. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display, Sensor and Electronics markets. An interesting property of quantum dots is their absorption spectrum. Nanoco's HEATWAVE™ quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectrum, rendering them useful for applications including image sensors. Another interesting property of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFIFIRELIDLIF
Date   Source Headline
1st Dec 202112:28 pmRNSAnnual General Meeting – Voting Results
30th Nov 20217:00 amRNSAGM Statement
18th Nov 20211:13 pmRNSDirector/PDMR Shareholding
9th Nov 20217:11 amRNSDirector/PDMR Shareholding
8th Nov 20217:00 amRNSDirector Appointment
5th Nov 202111:25 amRNSAdditional Work Package for European Customer
4th Nov 20216:20 pmRNSNotice of AGM
3rd Nov 20217:00 amRNSPreliminary Results
18th Oct 20216:10 pmRNSChange to final results announcement date
13th Oct 20219:30 amRNSPresentation via Investor Meet Company
8th Oct 20211:48 pmRNSNotice of Results
19th Aug 20217:00 amRNSNon-Executive Director Appointment
16th Jul 20214:41 pmRNSSecond Price Monitoring Extn
16th Jul 20214:35 pmRNSPrice Monitoring Extension
15th Jul 20217:00 amRNSNon-dilutive loan note subscription
5th Jul 20217:30 amRNSDevelopment Agreement
28th Jun 20217:00 amRNSLitigation update and non-dilutive debt facility
10th Jun 202111:33 amRNSBlocklisting Six-Monthly Return
24th May 202112:20 pmRNSHolding(s) in Company
20th May 20217:00 amRNSLitigation Update
13th May 20217:00 amRNSProject Extension
12th May 20217:00 amRNSLitigation Update
6th May 20213:28 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSInterim Results
29th Mar 20217:00 amRNSLitigation Update
26th Mar 20214:41 pmRNSSecond Price Monitoring Extn
26th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20213:36 pmRNSAmendment to Executive Director Service Terms
16th Mar 20212:30 pmRNSNotice of Results
10th Feb 20214:40 pmRNSSecond Price Monitoring Extn
10th Feb 20214:35 pmRNSPrice Monitoring Extension
25th Jan 20214:41 pmRNSSecond Price Monitoring Extn
25th Jan 20214:35 pmRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202011:40 amRNSBlocklisting Six-Monthly Return
3rd Dec 202012:10 pmRNSResult of AGM
3rd Dec 20207:00 amRNSAGM Statement
25th Nov 20207:00 amRNSGrant Funding Award for Life Sciences Project
17th Nov 20205:50 pmRNS2020 Annual Report and Notice of AGM
22nd Oct 20204:40 pmRNSSecond Price Monitoring Extn
22nd Oct 20204:35 pmRNSPrice Monitoring Extension
21st Oct 20203:16 pmRNSDirector/PDMR Shareholding
13th Oct 20207:00 amRNSPreliminary Results
7th Oct 20207:00 amRNSNotice of Results
25th Sep 20204:36 pmRNSPrice Monitoring Extension
1st Sep 20207:00 amRNSDirectorate Changes
21st Jul 202011:25 amRNSHolding(s) in Company
20th Jul 202012:35 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.